Maximum Dose of Crestor (Rosuvastatin)
The maximum dose of rosuvastatin (Crestor) is 40 mg once daily for most adult patients without contraindications. 1
Standard Dosing Framework
The FDA-approved dosing range for rosuvastatin is 5 to 40 mg once daily, taken at any time of day with or without food 1. For your patient currently on 20 mg daily with an LDL-C of 183 mg/dL, you can increase to 40 mg daily to achieve more aggressive LDL-C lowering, provided there are no contraindications.
Important Caveat About the 40 mg Dose
The 40 mg dose should be reserved only for patients who have not achieved their LDL-C goal on the 20 mg dose 1. Your patient with an LDL-C of 183 mg/dL clearly falls into this category and would be an appropriate candidate for dose escalation.
Dose Adjustments Based on Patient Characteristics
Severe Renal Impairment
- For patients with CrCl <30 mL/min/1.73 m² not on hemodialysis: Start at 5 mg daily and do not exceed 10 mg daily 2, 1
- This is a critical safety restriction, as rosuvastatin exposure increases significantly in severe renal impairment 1
- However, real-world data shows 44% of patients with eGFR <30 are inappropriately prescribed doses exceeding 10 mg 3, which is associated with increased risk of hematuria, proteinuria, and kidney failure 3
Asian Patients
- Consider starting at 5 mg daily due to approximately 2-fold higher rosuvastatin exposure compared to Caucasian patients 1
- This applies regardless of the target LDL-C goal
Drug Interactions Requiring Dose Limitation
- With cyclosporine: Limit to 5 mg daily 1
- With gemfibrozil: Limit to 10 mg daily (though combination should be avoided) 1
- With lopinavir/ritonavir: Limit to 10 mg daily 1
Expected LDL-C Reduction
When titrating from 20 mg to 40 mg, expect an additional 5-6% reduction in LDL-C 4. The 40 mg dose produces approximately 55-63% total LDL-C reduction from baseline 5, 6, compared to approximately 50% with 20 mg.
Clinical Context for Your Patient
With an LDL-C of 183 mg/dL on 20 mg rosuvastatin, your patient has achieved approximately 30-40% reduction from baseline (estimated baseline ~260-305 mg/dL). Increasing to 40 mg is appropriate and will provide additional LDL-C lowering, though you may also need to consider adding ezetimibe if the 40 mg dose alone doesn't achieve goal 7.
Monitoring After Dose Increase
- Recheck lipids in 2-4 weeks after titration 1
- Monitor for myopathy symptoms (though risk remains low at <0.03% with doses up to 40 mg) 5
- Check liver enzymes if not recently done, though clinically significant ALT elevations occur in only 0.2% of patients 8
Safety Profile at Maximum Dose
The 40 mg dose has been extensively studied with an acceptable safety profile 5. In over 12,569 patients representing 14,231 patient-years of treatment, myopathy occurred in ≤0.03% of patients on 10-40 mg doses, with no cases of rhabdomyolysis 5. The main additional consideration at 40 mg versus 20 mg is a slightly increased risk of proteinuria by dipstick testing 4, though this is generally not clinically significant in patients with normal renal function.